nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—TNF—Crohn's disease	0.254	0.678	CbGaD
Thalidomide—PTGS2—Crohn's disease	0.12	0.322	CbGaD
Thalidomide—PTGS2—Balsalazide—Crohn's disease	0.087	0.221	CbGbCtD
Thalidomide—PTGS1—Balsalazide—Crohn's disease	0.0735	0.187	CbGbCtD
Thalidomide—PTGS2—Mesalazine—Crohn's disease	0.0695	0.177	CbGbCtD
Thalidomide—PTGS1—Mesalazine—Crohn's disease	0.0587	0.149	CbGbCtD
Thalidomide—PTGS2—Sulfasalazine—Crohn's disease	0.0388	0.0989	CbGbCtD
Thalidomide—PTGS1—Sulfasalazine—Crohn's disease	0.0328	0.0835	CbGbCtD
Thalidomide—CYP3A5—Sulfasalazine—Crohn's disease	0.0197	0.0501	CbGbCtD
Thalidomide—CYP2C19—Prednisone—Crohn's disease	0.0127	0.0323	CbGbCtD
Thalidomide—Lenalidomide—TNFSF11—Crohn's disease	0.00397	0.726	CrCbGaD
Thalidomide—NFKB1—mouth—Crohn's disease	0.00272	0.0972	CbGeAlD
Thalidomide—FGFR2—mouth—Crohn's disease	0.00205	0.073	CbGeAlD
Thalidomide—NFKB1—mammalian vulva—Crohn's disease	0.00137	0.0491	CbGeAlD
Thalidomide—NFKB1—lymphoid tissue—Crohn's disease	0.00122	0.0436	CbGeAlD
Thalidomide—TNF—lymph node—Crohn's disease	0.00121	0.0431	CbGeAlD
Thalidomide—NFKB1—digestive system—Crohn's disease	0.00121	0.043	CbGeAlD
Thalidomide—FGFR2—epithelium—Crohn's disease	0.00119	0.0425	CbGeAlD
Thalidomide—CRBN—mammalian vulva—Crohn's disease	0.00115	0.0411	CbGeAlD
Thalidomide—FGFR2—smooth muscle tissue—Crohn's disease	0.00115	0.0409	CbGeAlD
Thalidomide—FGFR2—skin of body—Crohn's disease	0.00113	0.0404	CbGeAlD
Thalidomide—CRBN—lymphoid tissue—Crohn's disease	0.00102	0.0365	CbGeAlD
Thalidomide—CRBN—digestive system—Crohn's disease	0.00101	0.0361	CbGeAlD
Thalidomide—FGFR2—digestive system—Crohn's disease	0.000905	0.0323	CbGeAlD
Thalidomide—Pomalidomide—TNF—Crohn's disease	0.000756	0.138	CrCbGaD
Thalidomide—CYP1A1—mouth—Crohn's disease	0.00074	0.0264	CbGeAlD
Thalidomide—PTGS2—gall bladder—Crohn's disease	0.000699	0.0249	CbGeAlD
Thalidomide—NFKB1—lymph node—Crohn's disease	0.000688	0.0246	CbGeAlD
Thalidomide—PTGS2—mouth—Crohn's disease	0.000621	0.0222	CbGeAlD
Thalidomide—CRBN—lymph node—Crohn's disease	0.000577	0.0206	CbGeAlD
Thalidomide—CYP1A1—epithelium—Crohn's disease	0.000431	0.0154	CbGeAlD
Thalidomide—CYP1A1—skin of body—Crohn's disease	0.000409	0.0146	CbGeAlD
Thalidomide—CYP2C19—digestive system—Crohn's disease	0.000407	0.0145	CbGeAlD
Thalidomide—Lenalidomide—PTGS2—Crohn's disease	0.000386	0.0705	CrCbGaD
Thalidomide—PTGS1—epithelium—Crohn's disease	0.000378	0.0135	CbGeAlD
Thalidomide—CYP1A1—mammalian vulva—Crohn's disease	0.000373	0.0133	CbGeAlD
Thalidomide—PTGS1—smooth muscle tissue—Crohn's disease	0.000364	0.013	CbGeAlD
Thalidomide—PTGS2—epithelium—Crohn's disease	0.000362	0.0129	CbGeAlD
Thalidomide—PTGS1—skin of body—Crohn's disease	0.00036	0.0128	CbGeAlD
Thalidomide—Pomalidomide—PTGS2—Crohn's disease	0.000359	0.0655	CrCbGaD
Thalidomide—PTGS2—smooth muscle tissue—Crohn's disease	0.000348	0.0124	CbGeAlD
Thalidomide—PTGS2—skin of body—Crohn's disease	0.000344	0.0123	CbGeAlD
Thalidomide—CYP1A2—digestive system—Crohn's disease	0.000332	0.0119	CbGeAlD
Thalidomide—PTGS1—mammalian vulva—Crohn's disease	0.000328	0.0117	CbGeAlD
Thalidomide—CYP1A1—digestive system—Crohn's disease	0.000328	0.0117	CbGeAlD
Thalidomide—CYP3A5—digestive system—Crohn's disease	0.00032	0.0114	CbGeAlD
Thalidomide—CYP2C9—digestive system—Crohn's disease	0.000315	0.0113	CbGeAlD
Thalidomide—CYP2E1—lymphoid tissue—Crohn's disease	0.000302	0.0108	CbGeAlD
Thalidomide—CYP2E1—digestive system—Crohn's disease	0.000299	0.0107	CbGeAlD
Thalidomide—PTGS1—digestive system—Crohn's disease	0.000288	0.0103	CbGeAlD
Thalidomide—PTGS2—lymphoid tissue—Crohn's disease	0.000278	0.00994	CbGeAlD
Thalidomide—PTGS2—digestive system—Crohn's disease	0.000275	0.00982	CbGeAlD
Thalidomide—Eosinophilia—Mesalazine—Crohn's disease	0.000208	0.00202	CcSEcCtD
Thalidomide—Pneumonia—Azathioprine—Crohn's disease	0.000206	0.00201	CcSEcCtD
Thalidomide—Bronchospasm—Mesalazine—Crohn's disease	0.000206	0.00201	CcSEcCtD
Thalidomide—Pancreatitis—Mesalazine—Crohn's disease	0.000206	0.002	CcSEcCtD
Thalidomide—Infestation NOS—Azathioprine—Crohn's disease	0.000205	0.002	CcSEcCtD
Thalidomide—Infestation—Azathioprine—Crohn's disease	0.000205	0.002	CcSEcCtD
Thalidomide—Angina pectoris—Mesalazine—Crohn's disease	0.000204	0.00199	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Azathioprine—Crohn's disease	0.000203	0.00198	CcSEcCtD
Thalidomide—Bronchitis—Mesalazine—Crohn's disease	0.000202	0.00197	CcSEcCtD
Thalidomide—Amenorrhoea—Prednisone—Crohn's disease	0.000201	0.00196	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.0002	0.00195	CcSEcCtD
Thalidomide—Pancytopenia—Mesalazine—Crohn's disease	0.000199	0.00194	CcSEcCtD
Thalidomide—Neutropenia—Mesalazine—Crohn's disease	0.000196	0.00191	CcSEcCtD
Thalidomide—Viral infection—Prednisone—Crohn's disease	0.000196	0.00191	CcSEcCtD
Thalidomide—Upper respiratory tract infection—Mesalazine—Crohn's disease	0.000195	0.0019	CcSEcCtD
Thalidomide—Arthropathy—Prednisone—Crohn's disease	0.000194	0.0019	CcSEcCtD
Thalidomide—Pollakiuria—Mesalazine—Crohn's disease	0.000194	0.00189	CcSEcCtD
Thalidomide—Agranulocytosis—Azathioprine—Crohn's disease	0.000191	0.00187	CcSEcCtD
Thalidomide—Photosensitivity reaction—Mesalazine—Crohn's disease	0.000191	0.00187	CcSEcCtD
Thalidomide—Decreased appetite—Mercaptopurine—Crohn's disease	0.000191	0.00186	CcSEcCtD
Thalidomide—Weight increased—Mesalazine—Crohn's disease	0.000191	0.00186	CcSEcCtD
Thalidomide—Weight decreased—Mesalazine—Crohn's disease	0.00019	0.00185	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.00019	0.00185	CcSEcCtD
Thalidomide—Leukocytosis—Prednisone—Crohn's disease	0.000188	0.00183	CcSEcCtD
Thalidomide—Pneumonia—Mesalazine—Crohn's disease	0.000188	0.00183	CcSEcCtD
Thalidomide—CYP1A1—lymph node—Crohn's disease	0.000187	0.00668	CbGeAlD
Thalidomide—Infestation NOS—Mesalazine—Crohn's disease	0.000187	0.00182	CcSEcCtD
Thalidomide—Infestation—Mesalazine—Crohn's disease	0.000187	0.00182	CcSEcCtD
Thalidomide—Hypercholesterolaemia—Prednisone—Crohn's disease	0.000187	0.00182	CcSEcCtD
Thalidomide—Depression—Mesalazine—Crohn's disease	0.000186	0.00182	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Mesalazine—Crohn's disease	0.000185	0.00181	CcSEcCtD
Thalidomide—Renal failure—Mesalazine—Crohn's disease	0.000184	0.00179	CcSEcCtD
Thalidomide—Neuropathy peripheral—Mesalazine—Crohn's disease	0.000183	0.00179	CcSEcCtD
Thalidomide—Stomatitis—Mesalazine—Crohn's disease	0.000182	0.00178	CcSEcCtD
Thalidomide—Conjunctivitis—Mesalazine—Crohn's disease	0.000182	0.00177	CcSEcCtD
Thalidomide—Sweating—Mesalazine—Crohn's disease	0.000179	0.00175	CcSEcCtD
Thalidomide—Haematuria—Mesalazine—Crohn's disease	0.000178	0.00174	CcSEcCtD
Thalidomide—Epistaxis—Mesalazine—Crohn's disease	0.000176	0.00172	CcSEcCtD
Thalidomide—Sinusitis—Mesalazine—Crohn's disease	0.000175	0.00171	CcSEcCtD
Thalidomide—Agranulocytosis—Mesalazine—Crohn's disease	0.000174	0.0017	CcSEcCtD
Thalidomide—Erythema multiforme—Azathioprine—Crohn's disease	0.000174	0.0017	CcSEcCtD
Thalidomide—Body temperature increased—Mercaptopurine—Crohn's disease	0.000174	0.00169	CcSEcCtD
Thalidomide—Skin exfoliation—Prednisone—Crohn's disease	0.000169	0.00165	CcSEcCtD
Thalidomide—Rhinitis—Mesalazine—Crohn's disease	0.000168	0.00164	CcSEcCtD
Thalidomide—Hepatitis—Mesalazine—Crohn's disease	0.000168	0.00164	CcSEcCtD
Thalidomide—Pharyngitis—Mesalazine—Crohn's disease	0.000167	0.00162	CcSEcCtD
Thalidomide—Immune system disorder—Azathioprine—Crohn's disease	0.000166	0.00162	CcSEcCtD
Thalidomide—Mediastinal disorder—Azathioprine—Crohn's disease	0.000166	0.00162	CcSEcCtD
Thalidomide—Neuropathy—Prednisone—Crohn's disease	0.000166	0.00162	CcSEcCtD
Thalidomide—Urinary tract disorder—Mesalazine—Crohn's disease	0.000166	0.00162	CcSEcCtD
Thalidomide—Oedema peripheral—Mesalazine—Crohn's disease	0.000165	0.00161	CcSEcCtD
Thalidomide—Chills—Azathioprine—Crohn's disease	0.000165	0.00161	CcSEcCtD
Thalidomide—Arrhythmia—Azathioprine—Crohn's disease	0.000165	0.0016	CcSEcCtD
Thalidomide—Urethral disorder—Mesalazine—Crohn's disease	0.000164	0.0016	CcSEcCtD
Thalidomide—PTGS1—lymph node—Crohn's disease	0.000164	0.00587	CbGeAlD
Thalidomide—Alopecia—Azathioprine—Crohn's disease	0.000163	0.00159	CcSEcCtD
Thalidomide—Hypersensitivity—Mercaptopurine—Crohn's disease	0.000162	0.00158	CcSEcCtD
Thalidomide—Oesophagitis—Prednisone—Crohn's disease	0.000162	0.00158	CcSEcCtD
Thalidomide—Erythema multiforme—Mesalazine—Crohn's disease	0.000159	0.00155	CcSEcCtD
Thalidomide—Pulmonary oedema—Prednisone—Crohn's disease	0.000157	0.00153	CcSEcCtD
Thalidomide—PTGS2—lymph node—Crohn's disease	0.000157	0.00561	CbGeAlD
Thalidomide—Eye disorder—Mesalazine—Crohn's disease	0.000157	0.00153	CcSEcCtD
Thalidomide—Tinnitus—Mesalazine—Crohn's disease	0.000156	0.00153	CcSEcCtD
Thalidomide—Cardiac disorder—Mesalazine—Crohn's disease	0.000156	0.00152	CcSEcCtD
Thalidomide—Hyperkinesia—Prednisone—Crohn's disease	0.000154	0.0015	CcSEcCtD
Thalidomide—Sepsis—Prednisone—Crohn's disease	0.000153	0.0015	CcSEcCtD
Thalidomide—Angiopathy—Mesalazine—Crohn's disease	0.000152	0.00148	CcSEcCtD
Thalidomide—Euphoric mood—Prednisone—Crohn's disease	0.000152	0.00148	CcSEcCtD
Thalidomide—Immune system disorder—Mesalazine—Crohn's disease	0.000152	0.00148	CcSEcCtD
Thalidomide—Mediastinal disorder—Mesalazine—Crohn's disease	0.000151	0.00147	CcSEcCtD
Thalidomide—Chills—Mesalazine—Crohn's disease	0.000151	0.00147	CcSEcCtD
Thalidomide—Diarrhoea—Mercaptopurine—Crohn's disease	0.00015	0.00147	CcSEcCtD
Thalidomide—Ill-defined disorder—Azathioprine—Crohn's disease	0.000149	0.00145	CcSEcCtD
Thalidomide—Alopecia—Mesalazine—Crohn's disease	0.000148	0.00145	CcSEcCtD
Thalidomide—Thrombophlebitis—Prednisone—Crohn's disease	0.000148	0.00145	CcSEcCtD
Thalidomide—Anaemia—Azathioprine—Crohn's disease	0.000148	0.00145	CcSEcCtD
Thalidomide—Diabetes mellitus—Prednisone—Crohn's disease	0.000148	0.00144	CcSEcCtD
Thalidomide—Mental disorder—Mesalazine—Crohn's disease	0.000147	0.00143	CcSEcCtD
Thalidomide—Malaise—Azathioprine—Crohn's disease	0.000145	0.00141	CcSEcCtD
Thalidomide—Flatulence—Mesalazine—Crohn's disease	0.000144	0.0014	CcSEcCtD
Thalidomide—Leukopenia—Azathioprine—Crohn's disease	0.000144	0.0014	CcSEcCtD
Thalidomide—Vascular purpura—Prednisone—Crohn's disease	0.000143	0.0014	CcSEcCtD
Thalidomide—Tension—Mesalazine—Crohn's disease	0.000143	0.0014	CcSEcCtD
Thalidomide—Dysgeusia—Mesalazine—Crohn's disease	0.000143	0.00139	CcSEcCtD
Thalidomide—Nervousness—Mesalazine—Crohn's disease	0.000142	0.00138	CcSEcCtD
Thalidomide—Cardiac failure congestive—Prednisone—Crohn's disease	0.000142	0.00138	CcSEcCtD
Thalidomide—Back pain—Mesalazine—Crohn's disease	0.000141	0.00138	CcSEcCtD
Thalidomide—Muscle spasms—Mesalazine—Crohn's disease	0.00014	0.00137	CcSEcCtD
Thalidomide—Vomiting—Mercaptopurine—Crohn's disease	0.00014	0.00136	CcSEcCtD
Thalidomide—Injury—Prednisone—Crohn's disease	0.00014	0.00136	CcSEcCtD
Thalidomide—Rash—Mercaptopurine—Crohn's disease	0.000138	0.00135	CcSEcCtD
Thalidomide—Dermatitis—Mercaptopurine—Crohn's disease	0.000138	0.00135	CcSEcCtD
Thalidomide—Vision blurred—Mesalazine—Crohn's disease	0.000138	0.00134	CcSEcCtD
Thalidomide—Tremor—Mesalazine—Crohn's disease	0.000137	0.00133	CcSEcCtD
Thalidomide—Increased appetite—Prednisone—Crohn's disease	0.000137	0.00133	CcSEcCtD
Thalidomide—Amnesia—Prednisone—Crohn's disease	0.000137	0.00133	CcSEcCtD
Thalidomide—Myalgia—Azathioprine—Crohn's disease	0.000137	0.00133	CcSEcCtD
Thalidomide—Arthralgia—Azathioprine—Crohn's disease	0.000137	0.00133	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.000136	0.00132	CcSEcCtD
Thalidomide—Ill-defined disorder—Mesalazine—Crohn's disease	0.000136	0.00132	CcSEcCtD
Thalidomide—Anaemia—Mesalazine—Crohn's disease	0.000135	0.00132	CcSEcCtD
Thalidomide—Discomfort—Azathioprine—Crohn's disease	0.000135	0.00132	CcSEcCtD
Thalidomide—Angioedema—Mesalazine—Crohn's disease	0.000133	0.0013	CcSEcCtD
Thalidomide—Purpura—Prednisone—Crohn's disease	0.000133	0.0013	CcSEcCtD
Thalidomide—Malaise—Mesalazine—Crohn's disease	0.000132	0.00128	CcSEcCtD
Thalidomide—Cardiac failure—Prednisone—Crohn's disease	0.000131	0.00128	CcSEcCtD
Thalidomide—Vertigo—Mesalazine—Crohn's disease	0.000131	0.00128	CcSEcCtD
Thalidomide—Syncope—Mesalazine—Crohn's disease	0.000131	0.00128	CcSEcCtD
Thalidomide—Lethargy—Prednisone—Crohn's disease	0.000131	0.00128	CcSEcCtD
Thalidomide—Leukopenia—Mesalazine—Crohn's disease	0.000131	0.00127	CcSEcCtD
Thalidomide—Nausea—Mercaptopurine—Crohn's disease	0.00013	0.00127	CcSEcCtD
Thalidomide—Infection—Azathioprine—Crohn's disease	0.00013	0.00127	CcSEcCtD
Thalidomide—Palpitations—Mesalazine—Crohn's disease	0.000129	0.00126	CcSEcCtD
Thalidomide—Loss of consciousness—Mesalazine—Crohn's disease	0.000128	0.00125	CcSEcCtD
Thalidomide—Osteoarthritis—Prednisone—Crohn's disease	0.000128	0.00125	CcSEcCtD
Thalidomide—Gastrointestinal haemorrhage—Prednisone—Crohn's disease	0.000128	0.00125	CcSEcCtD
Thalidomide—Thrombocytopenia—Azathioprine—Crohn's disease	0.000128	0.00125	CcSEcCtD
Thalidomide—Cough—Mesalazine—Crohn's disease	0.000127	0.00124	CcSEcCtD
Thalidomide—Skin disorder—Azathioprine—Crohn's disease	0.000127	0.00124	CcSEcCtD
Thalidomide—Affect lability—Prednisone—Crohn's disease	0.000126	0.00123	CcSEcCtD
Thalidomide—Hypertension—Mesalazine—Crohn's disease	0.000126	0.00123	CcSEcCtD
Thalidomide—Psychotic disorder—Prednisone—Crohn's disease	0.000125	0.00122	CcSEcCtD
Thalidomide—Chest pain—Mesalazine—Crohn's disease	0.000124	0.00121	CcSEcCtD
Thalidomide—Arthralgia—Mesalazine—Crohn's disease	0.000124	0.00121	CcSEcCtD
Thalidomide—Myalgia—Mesalazine—Crohn's disease	0.000124	0.00121	CcSEcCtD
Thalidomide—Anxiety—Mesalazine—Crohn's disease	0.000124	0.00121	CcSEcCtD
Thalidomide—Face oedema—Prednisone—Crohn's disease	0.000124	0.00121	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.000123	0.0012	CcSEcCtD
Thalidomide—Discomfort—Mesalazine—Crohn's disease	0.000123	0.0012	CcSEcCtD
Thalidomide—Hypotension—Azathioprine—Crohn's disease	0.000122	0.00119	CcSEcCtD
Thalidomide—Cardiac arrest—Prednisone—Crohn's disease	0.000122	0.00119	CcSEcCtD
Thalidomide—Dry mouth—Mesalazine—Crohn's disease	0.000122	0.00119	CcSEcCtD
Thalidomide—Mood swings—Prednisone—Crohn's disease	0.000122	0.00119	CcSEcCtD
Thalidomide—Confusional state—Mesalazine—Crohn's disease	0.00012	0.00117	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.000119	0.00116	CcSEcCtD
Thalidomide—Oedema—Mesalazine—Crohn's disease	0.000119	0.00116	CcSEcCtD
Thalidomide—Infection—Mesalazine—Crohn's disease	0.000118	0.00115	CcSEcCtD
Thalidomide—Dry skin—Prednisone—Crohn's disease	0.000118	0.00115	CcSEcCtD
Thalidomide—Shock—Mesalazine—Crohn's disease	0.000117	0.00114	CcSEcCtD
Thalidomide—Nervous system disorder—Mesalazine—Crohn's disease	0.000117	0.00114	CcSEcCtD
Thalidomide—Hypokalaemia—Prednisone—Crohn's disease	0.000117	0.00114	CcSEcCtD
Thalidomide—Thrombocytopenia—Mesalazine—Crohn's disease	0.000117	0.00114	CcSEcCtD
Thalidomide—Tachycardia—Mesalazine—Crohn's disease	0.000116	0.00113	CcSEcCtD
Thalidomide—Skin disorder—Mesalazine—Crohn's disease	0.000116	0.00113	CcSEcCtD
Thalidomide—Hyperhidrosis—Mesalazine—Crohn's disease	0.000115	0.00112	CcSEcCtD
Thalidomide—Anorexia—Mesalazine—Crohn's disease	0.000114	0.00111	CcSEcCtD
Thalidomide—Alanine aminotransferase increased—Prednisone—Crohn's disease	0.000113	0.0011	CcSEcCtD
Thalidomide—Muscular weakness—Prednisone—Crohn's disease	0.000113	0.0011	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.000113	0.0011	CcSEcCtD
Thalidomide—Abdominal distension—Prednisone—Crohn's disease	0.000112	0.00109	CcSEcCtD
Thalidomide—Hypotension—Mesalazine—Crohn's disease	0.000111	0.00109	CcSEcCtD
Thalidomide—Pancreatitis—Prednisone—Crohn's disease	0.000109	0.00106	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.000109	0.00106	CcSEcCtD
Thalidomide—Feeling abnormal—Azathioprine—Crohn's disease	0.000108	0.00105	CcSEcCtD
Thalidomide—Insomnia—Mesalazine—Crohn's disease	0.000108	0.00105	CcSEcCtD
Thalidomide—Paraesthesia—Mesalazine—Crohn's disease	0.000107	0.00104	CcSEcCtD
Thalidomide—Gastrointestinal pain—Azathioprine—Crohn's disease	0.000107	0.00104	CcSEcCtD
Thalidomide—Dyspnoea—Mesalazine—Crohn's disease	0.000106	0.00104	CcSEcCtD
Thalidomide—Somnolence—Mesalazine—Crohn's disease	0.000106	0.00103	CcSEcCtD
Thalidomide—Dyspepsia—Mesalazine—Crohn's disease	0.000105	0.00102	CcSEcCtD
Thalidomide—Neutropenia—Prednisone—Crohn's disease	0.000104	0.00101	CcSEcCtD
Thalidomide—Decreased appetite—Mesalazine—Crohn's disease	0.000104	0.00101	CcSEcCtD
Thalidomide—Abdominal pain—Azathioprine—Crohn's disease	0.000103	0.00101	CcSEcCtD
Thalidomide—Body temperature increased—Azathioprine—Crohn's disease	0.000103	0.00101	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.000103	0.001	CcSEcCtD
Thalidomide—Fatigue—Mesalazine—Crohn's disease	0.000103	0.001	CcSEcCtD
Thalidomide—Erectile dysfunction—Prednisone—Crohn's disease	0.000102	0.000996	CcSEcCtD
Thalidomide—Pain—Mesalazine—Crohn's disease	0.000102	0.000994	CcSEcCtD
Thalidomide—Constipation—Mesalazine—Crohn's disease	0.000102	0.000994	CcSEcCtD
Thalidomide—Weight increased—Prednisone—Crohn's disease	0.000101	0.000984	CcSEcCtD
Thalidomide—Weight decreased—Prednisone—Crohn's disease	0.0001	0.000978	CcSEcCtD
Thalidomide—Hyperglycaemia—Prednisone—Crohn's disease	0.0001	0.000976	CcSEcCtD
Thalidomide—Depression—Prednisone—Crohn's disease	9.86e-05	0.000962	CcSEcCtD
Thalidomide—Feeling abnormal—Mesalazine—Crohn's disease	9.82e-05	0.000958	CcSEcCtD
Thalidomide—Acute coronary syndrome—Prednisone—Crohn's disease	9.75e-05	0.000951	CcSEcCtD
Thalidomide—Gastrointestinal pain—Mesalazine—Crohn's disease	9.75e-05	0.000951	CcSEcCtD
Thalidomide—Myocardial infarction—Prednisone—Crohn's disease	9.69e-05	0.000945	CcSEcCtD
Thalidomide—Neuropathy peripheral—Prednisone—Crohn's disease	9.69e-05	0.000945	CcSEcCtD
Thalidomide—Hypersensitivity—Azathioprine—Crohn's disease	9.64e-05	0.00094	CcSEcCtD
Thalidomide—Urticaria—Mesalazine—Crohn's disease	9.47e-05	0.000923	CcSEcCtD
Thalidomide—Body temperature increased—Mesalazine—Crohn's disease	9.42e-05	0.000919	CcSEcCtD
Thalidomide—Abdominal pain—Mesalazine—Crohn's disease	9.42e-05	0.000919	CcSEcCtD
Thalidomide—Bradycardia—Prednisone—Crohn's disease	9.04e-05	0.000881	CcSEcCtD
Thalidomide—Diarrhoea—Azathioprine—Crohn's disease	8.95e-05	0.000873	CcSEcCtD
Thalidomide—Hypersensitivity—Mesalazine—Crohn's disease	8.78e-05	0.000856	CcSEcCtD
Thalidomide—Dizziness—Azathioprine—Crohn's disease	8.65e-05	0.000844	CcSEcCtD
Thalidomide—Asthenia—Mesalazine—Crohn's disease	8.55e-05	0.000834	CcSEcCtD
Thalidomide—Pruritus—Mesalazine—Crohn's disease	8.43e-05	0.000822	CcSEcCtD
Thalidomide—Vomiting—Azathioprine—Crohn's disease	8.32e-05	0.000811	CcSEcCtD
Thalidomide—Eye disorder—Prednisone—Crohn's disease	8.3e-05	0.000809	CcSEcCtD
Thalidomide—Rash—Azathioprine—Crohn's disease	8.25e-05	0.000805	CcSEcCtD
Thalidomide—Dermatitis—Azathioprine—Crohn's disease	8.24e-05	0.000804	CcSEcCtD
Thalidomide—Headache—Azathioprine—Crohn's disease	8.2e-05	0.000799	CcSEcCtD
Thalidomide—Diarrhoea—Mesalazine—Crohn's disease	8.16e-05	0.000795	CcSEcCtD
Thalidomide—Angiopathy—Prednisone—Crohn's disease	8.05e-05	0.000785	CcSEcCtD
Thalidomide—Immune system disorder—Prednisone—Crohn's disease	8.02e-05	0.000782	CcSEcCtD
Thalidomide—Arrhythmia—Prednisone—Crohn's disease	7.93e-05	0.000773	CcSEcCtD
Thalidomide—Dizziness—Mesalazine—Crohn's disease	7.88e-05	0.000769	CcSEcCtD
Thalidomide—Alopecia—Prednisone—Crohn's disease	7.84e-05	0.000765	CcSEcCtD
Thalidomide—Mental disorder—Prednisone—Crohn's disease	7.78e-05	0.000758	CcSEcCtD
Thalidomide—Nausea—Azathioprine—Crohn's disease	7.77e-05	0.000758	CcSEcCtD
Thalidomide—Malnutrition—Prednisone—Crohn's disease	7.73e-05	0.000754	CcSEcCtD
Thalidomide—Vomiting—Mesalazine—Crohn's disease	7.58e-05	0.000739	CcSEcCtD
Thalidomide—Rash—Mesalazine—Crohn's disease	7.52e-05	0.000733	CcSEcCtD
Thalidomide—Dermatitis—Mesalazine—Crohn's disease	7.51e-05	0.000732	CcSEcCtD
Thalidomide—Headache—Mesalazine—Crohn's disease	7.47e-05	0.000728	CcSEcCtD
Thalidomide—Vision blurred—Prednisone—Crohn's disease	7.28e-05	0.00071	CcSEcCtD
Thalidomide—Ill-defined disorder—Prednisone—Crohn's disease	7.17e-05	0.000699	CcSEcCtD
Thalidomide—Anaemia—Prednisone—Crohn's disease	7.14e-05	0.000697	CcSEcCtD
Thalidomide—Agitation—Prednisone—Crohn's disease	7.1e-05	0.000693	CcSEcCtD
Thalidomide—Nausea—Mesalazine—Crohn's disease	7.08e-05	0.00069	CcSEcCtD
Thalidomide—Angioedema—Prednisone—Crohn's disease	7.06e-05	0.000689	CcSEcCtD
Thalidomide—Malaise—Prednisone—Crohn's disease	6.97e-05	0.00068	CcSEcCtD
Thalidomide—Vertigo—Prednisone—Crohn's disease	6.94e-05	0.000677	CcSEcCtD
Thalidomide—Syncope—Prednisone—Crohn's disease	6.93e-05	0.000676	CcSEcCtD
Thalidomide—Loss of consciousness—Prednisone—Crohn's disease	6.79e-05	0.000662	CcSEcCtD
Thalidomide—Convulsion—Prednisone—Crohn's disease	6.7e-05	0.000653	CcSEcCtD
Thalidomide—Hypertension—Prednisone—Crohn's disease	6.67e-05	0.000651	CcSEcCtD
Thalidomide—Arthralgia—Prednisone—Crohn's disease	6.58e-05	0.000642	CcSEcCtD
Thalidomide—Myalgia—Prednisone—Crohn's disease	6.58e-05	0.000642	CcSEcCtD
Thalidomide—Anxiety—Prednisone—Crohn's disease	6.56e-05	0.000639	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	6.53e-05	0.000637	CcSEcCtD
Thalidomide—Discomfort—Prednisone—Crohn's disease	6.5e-05	0.000634	CcSEcCtD
Thalidomide—Oedema—Prednisone—Crohn's disease	6.31e-05	0.000615	CcSEcCtD
Thalidomide—Infection—Prednisone—Crohn's disease	6.27e-05	0.000611	CcSEcCtD
Thalidomide—Shock—Prednisone—Crohn's disease	6.21e-05	0.000605	CcSEcCtD
Thalidomide—Nervous system disorder—Prednisone—Crohn's disease	6.19e-05	0.000603	CcSEcCtD
Thalidomide—Tachycardia—Prednisone—Crohn's disease	6.16e-05	0.0006	CcSEcCtD
Thalidomide—Skin disorder—Prednisone—Crohn's disease	6.13e-05	0.000597	CcSEcCtD
Thalidomide—Hyperhidrosis—Prednisone—Crohn's disease	6.1e-05	0.000595	CcSEcCtD
Thalidomide—Anorexia—Prednisone—Crohn's disease	6.01e-05	0.000586	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Prednisone—Crohn's disease	5.75e-05	0.00056	CcSEcCtD
Thalidomide—Insomnia—Prednisone—Crohn's disease	5.7e-05	0.000556	CcSEcCtD
Thalidomide—Paraesthesia—Prednisone—Crohn's disease	5.66e-05	0.000552	CcSEcCtD
Thalidomide—Dyspepsia—Prednisone—Crohn's disease	5.55e-05	0.000541	CcSEcCtD
Thalidomide—Decreased appetite—Prednisone—Crohn's disease	5.48e-05	0.000535	CcSEcCtD
Thalidomide—Fatigue—Prednisone—Crohn's disease	5.44e-05	0.00053	CcSEcCtD
Thalidomide—Constipation—Prednisone—Crohn's disease	5.39e-05	0.000526	CcSEcCtD
Thalidomide—Feeling abnormal—Prednisone—Crohn's disease	5.2e-05	0.000507	CcSEcCtD
Thalidomide—Gastrointestinal pain—Prednisone—Crohn's disease	5.16e-05	0.000503	CcSEcCtD
Thalidomide—Urticaria—Prednisone—Crohn's disease	5.01e-05	0.000489	CcSEcCtD
Thalidomide—Abdominal pain—Prednisone—Crohn's disease	4.99e-05	0.000486	CcSEcCtD
Thalidomide—Body temperature increased—Prednisone—Crohn's disease	4.99e-05	0.000486	CcSEcCtD
Thalidomide—Hypersensitivity—Prednisone—Crohn's disease	4.65e-05	0.000453	CcSEcCtD
Thalidomide—Asthenia—Prednisone—Crohn's disease	4.53e-05	0.000441	CcSEcCtD
Thalidomide—Pruritus—Prednisone—Crohn's disease	4.46e-05	0.000435	CcSEcCtD
Thalidomide—Diarrhoea—Prednisone—Crohn's disease	4.32e-05	0.000421	CcSEcCtD
Thalidomide—Dizziness—Prednisone—Crohn's disease	4.17e-05	0.000407	CcSEcCtD
Thalidomide—Vomiting—Prednisone—Crohn's disease	4.01e-05	0.000391	CcSEcCtD
Thalidomide—Rash—Prednisone—Crohn's disease	3.98e-05	0.000388	CcSEcCtD
Thalidomide—Dermatitis—Prednisone—Crohn's disease	3.97e-05	0.000387	CcSEcCtD
Thalidomide—Headache—Prednisone—Crohn's disease	3.95e-05	0.000385	CcSEcCtD
Thalidomide—Nausea—Prednisone—Crohn's disease	3.75e-05	0.000365	CcSEcCtD
Thalidomide—FGFR2—Immune System—CCR6—Crohn's disease	2.62e-05	0.00027	CbGpPWpGaD
Thalidomide—TNF—Toll-like Receptor Signaling Pathway—IL6—Crohn's disease	2.62e-05	0.00027	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IL1B—Crohn's disease	2.62e-05	0.000269	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	2.58e-05	0.000265	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—CXCL8—Crohn's disease	2.57e-05	0.000264	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCR9—Crohn's disease	2.56e-05	0.000264	CbGpPWpGaD
Thalidomide—FGFR2—Disease—SLC11A1—Crohn's disease	2.56e-05	0.000263	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	2.55e-05	0.000263	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	2.54e-05	0.000261	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PTPN2—Crohn's disease	2.53e-05	0.00026	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PLA2G4F—Crohn's disease	2.53e-05	0.00026	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by SCF-KIT—IL6—Crohn's disease	2.52e-05	0.000259	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—GPR65—Crohn's disease	2.51e-05	0.000258	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—RBX1—Crohn's disease	2.5e-05	0.000257	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	2.48e-05	0.000255	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—IL1B—Crohn's disease	2.46e-05	0.000253	CbGpPWpGaD
Thalidomide—NFKB1—Myometrial Relaxation and Contraction Pathways—IL6—Crohn's disease	2.46e-05	0.000253	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—IL6—Crohn's disease	2.45e-05	0.000252	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—IL6—Crohn's disease	2.41e-05	0.000248	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PTPN2—Crohn's disease	2.4e-05	0.000247	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—GPR65—Crohn's disease	2.38e-05	0.000245	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—RBX1—Crohn's disease	2.37e-05	0.000244	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—IL6—Crohn's disease	2.37e-05	0.000244	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CRP—Crohn's disease	2.35e-05	0.000242	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—IL6—Crohn's disease	2.33e-05	0.00024	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—SMAD3—Crohn's disease	2.32e-05	0.000239	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—STAT3—Crohn's disease	2.3e-05	0.000237	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—IL6—Crohn's disease	2.3e-05	0.000236	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signal transduction—IL6—Crohn's disease	2.26e-05	0.000233	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—TNF—Crohn's disease	2.26e-05	0.000233	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—TLR4—Crohn's disease	2.26e-05	0.000232	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—IL6—Crohn's disease	2.25e-05	0.000232	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB2—IL6—Crohn's disease	2.24e-05	0.000231	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CRP—Crohn's disease	2.23e-05	0.00023	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—IL6—Crohn's disease	2.23e-05	0.00023	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—IL6—Crohn's disease	2.21e-05	0.000228	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—STAT3—Crohn's disease	2.19e-05	0.000226	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—UBE2D1—Crohn's disease	2.19e-05	0.000226	CbGpPWpGaD
Thalidomide—FGFR2—Disease—RBX1—Crohn's disease	2.19e-05	0.000226	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HSPA1B—Crohn's disease	2.19e-05	0.000226	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	2.17e-05	0.000223	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	2.17e-05	0.000223	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—STAT3—Crohn's disease	2.16e-05	0.000222	CbGpPWpGaD
Thalidomide—TNF—Adipogenesis—IL6—Crohn's disease	2.16e-05	0.000222	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—MTMR3—Crohn's disease	2.15e-05	0.000221	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—Crohn's disease	2.15e-05	0.000221	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—Crohn's disease	2.15e-05	0.000221	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—TLR4—Crohn's disease	2.14e-05	0.00022	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—RIPK2—Crohn's disease	2.13e-05	0.000219	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—ITGA4—Crohn's disease	2.13e-05	0.000219	CbGpPWpGaD
Thalidomide—NFKB1—Cellular Senescence—IL6—Crohn's disease	2.13e-05	0.000219	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—IL6—Crohn's disease	2.1e-05	0.000216	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—IL6—Crohn's disease	2.1e-05	0.000216	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—IL6—Crohn's disease	2.1e-05	0.000216	CbGpPWpGaD
Thalidomide—PTGS2—Disease—RSPO3—Crohn's disease	2.09e-05	0.000216	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—UBE2D1—Crohn's disease	2.08e-05	0.000214	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—IL6—Crohn's disease	2.08e-05	0.000214	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—ICAM1—Crohn's disease	2.08e-05	0.000214	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL3—Crohn's disease	2.07e-05	0.000213	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—IL6—Crohn's disease	2.06e-05	0.000212	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—IL6—Crohn's disease	2.05e-05	0.000211	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—STAT3—Crohn's disease	2.05e-05	0.000211	CbGpPWpGaD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL6—Crohn's disease	2.05e-05	0.00021	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	2.03e-05	0.000209	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—RIPK2—Crohn's disease	2.02e-05	0.000208	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—ITGA4—Crohn's disease	2.02e-05	0.000208	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PLA2G4F—Crohn's disease	2.01e-05	0.000207	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—RASGRP1—Crohn's disease	2.01e-05	0.000206	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD79A—Crohn's disease	2e-05	0.000206	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TYK2—Crohn's disease	1.99e-05	0.000205	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SEL1L—Crohn's disease	1.99e-05	0.000204	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	1.98e-05	0.000203	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—ICAM1—Crohn's disease	1.97e-05	0.000203	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL3—Crohn's disease	1.97e-05	0.000203	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—TAB1—Crohn's disease	1.96e-05	0.000202	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—NOD2—Crohn's disease	1.93e-05	0.000198	CbGpPWpGaD
Thalidomide—FGFR2—Disease—UBE2D1—Crohn's disease	1.92e-05	0.000198	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—RASGRP1—Crohn's disease	1.9e-05	0.000196	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—JAK2—Crohn's disease	1.9e-05	0.000195	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD79A—Crohn's disease	1.9e-05	0.000195	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PLA2G4F—Crohn's disease	1.89e-05	0.000194	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PLA2G4F—Crohn's disease	1.89e-05	0.000194	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—IL6—Crohn's disease	1.86e-05	0.000192	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—TAB1—Crohn's disease	1.86e-05	0.000192	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—IL6—Crohn's disease	1.86e-05	0.000191	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	1.85e-05	0.000191	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—NOD2—Crohn's disease	1.83e-05	0.000188	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—IL6—Crohn's disease	1.82e-05	0.000188	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—SOCS1—Crohn's disease	1.82e-05	0.000187	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCR6—Crohn's disease	1.79e-05	0.000184	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TNF—Crohn's disease	1.79e-05	0.000184	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PLA2G4F—Crohn's disease	1.78e-05	0.000183	CbGpPWpGaD
Thalidomide—PTGS2—Disease—LTF—Crohn's disease	1.78e-05	0.000183	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—TYK2—Crohn's disease	1.76e-05	0.000181	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—SOCS1—Crohn's disease	1.72e-05	0.000177	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—MTMR3—Crohn's disease	1.71e-05	0.000176	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCR6—Crohn's disease	1.7e-05	0.000175	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	1.69e-05	0.000174	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—JAK2—Crohn's disease	1.68e-05	0.000173	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—FADS1—Crohn's disease	1.67e-05	0.000172	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—TYK2—Crohn's disease	1.67e-05	0.000172	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL18—Crohn's disease	1.64e-05	0.000168	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—RBX1—Crohn's disease	1.62e-05	0.000166	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—IL6—Crohn's disease	1.61e-05	0.000165	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—MTMR3—Crohn's disease	1.61e-05	0.000165	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—MTMR3—Crohn's disease	1.6e-05	0.000165	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—JAK2—Crohn's disease	1.59e-05	0.000164	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CD4—Crohn's disease	1.59e-05	0.000164	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	1.58e-05	0.000163	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PTGER4—Crohn's disease	1.57e-05	0.000162	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GPX4—Crohn's disease	1.57e-05	0.000161	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL18—Crohn's disease	1.55e-05	0.00016	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—RBX1—Crohn's disease	1.53e-05	0.000158	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IL6—Crohn's disease	1.53e-05	0.000158	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CD4—Crohn's disease	1.53e-05	0.000157	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—TYK2—Crohn's disease	1.52e-05	0.000156	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GCKR—Crohn's disease	1.51e-05	0.000156	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MTMR3—Crohn's disease	1.51e-05	0.000156	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CD4—Crohn's disease	1.51e-05	0.000155	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—IL6—Crohn's disease	1.51e-05	0.000155	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PTGER4—Crohn's disease	1.49e-05	0.000154	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PLA2G4F—Crohn's disease	1.46e-05	0.00015	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL2RA—Crohn's disease	1.45e-05	0.00015	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CD4—Crohn's disease	1.45e-05	0.000149	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—JAK2—Crohn's disease	1.45e-05	0.000149	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—IL6—Crohn's disease	1.44e-05	0.000148	CbGpPWpGaD
Thalidomide—PTGS2—Disease—GCKR—Crohn's disease	1.44e-05	0.000148	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—IL6—Crohn's disease	1.43e-05	0.000147	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—UBE2D1—Crohn's disease	1.42e-05	0.000146	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—STAT3—Crohn's disease	1.39e-05	0.000143	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL2RA—Crohn's disease	1.38e-05	0.000142	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—RIPK2—Crohn's disease	1.38e-05	0.000142	CbGpPWpGaD
Thalidomide—FGFR2—Disease—SMAD3—Crohn's disease	1.37e-05	0.000141	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CRP—Crohn's disease	1.37e-05	0.000141	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—UBE2D1—Crohn's disease	1.35e-05	0.000138	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL3—Crohn's disease	1.34e-05	0.000138	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—FADS1—Crohn's disease	1.33e-05	0.000137	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PLA2G4F—Crohn's disease	1.33e-05	0.000137	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—TLR4—Crohn's disease	1.31e-05	0.000135	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—RIPK2—Crohn's disease	1.3e-05	0.000134	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CRP—Crohn's disease	1.3e-05	0.000134	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—RASGRP1—Crohn's disease	1.3e-05	0.000133	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL3—Crohn's disease	1.27e-05	0.000131	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SLC11A1—Crohn's disease	1.27e-05	0.000131	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—ICAM1—Crohn's disease	1.26e-05	0.00013	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—FADS1—Crohn's disease	1.25e-05	0.000129	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—FADS1—Crohn's disease	1.25e-05	0.000129	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—TLR4—Crohn's disease	1.25e-05	0.000128	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GPX4—Crohn's disease	1.25e-05	0.000128	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MTMR3—Crohn's disease	1.24e-05	0.000128	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—RASGRP1—Crohn's disease	1.23e-05	0.000127	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	1.22e-05	0.000125	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TNF—Crohn's disease	1.21e-05	0.000124	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GCKR—Crohn's disease	1.2e-05	0.000124	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—ICAM1—Crohn's disease	1.2e-05	0.000123	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—FADS1—Crohn's disease	1.18e-05	0.000121	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SOCS1—Crohn's disease	1.18e-05	0.000121	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GPX4—Crohn's disease	1.17e-05	0.000121	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GPX4—Crohn's disease	1.17e-05	0.00012	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PLA2G4F—Crohn's disease	1.14e-05	0.000117	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GCKR—Crohn's disease	1.13e-05	0.000117	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MTMR3—Crohn's disease	1.13e-05	0.000116	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GCKR—Crohn's disease	1.13e-05	0.000116	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SOCS1—Crohn's disease	1.11e-05	0.000115	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GPX4—Crohn's disease	1.11e-05	0.000114	CbGpPWpGaD
Thalidomide—PTGS2—Disease—RBX1—Crohn's disease	1.09e-05	0.000112	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HSPA1B—Crohn's disease	1.09e-05	0.000112	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	1.08e-05	0.000111	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GCKR—Crohn's disease	1.07e-05	0.00011	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—STAT3—Crohn's disease	1.06e-05	0.000109	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—TYK2—Crohn's disease	1.02e-05	0.000105	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SMAD3—Crohn's disease	1.01e-05	0.000104	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—JAK2—Crohn's disease	9.77e-06	0.000101	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—IL6—Crohn's disease	9.73e-06	0.0001	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—TYK2—Crohn's disease	9.71e-06	0.0001	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MTMR3—Crohn's disease	9.66e-06	9.94e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—FADS1—Crohn's disease	9.66e-06	9.94e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SMAD3—Crohn's disease	9.63e-06	9.91e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IFNG—Crohn's disease	9.59e-06	9.87e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—UBE2D1—Crohn's disease	9.54e-06	9.82e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	9.47e-06	9.75e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL2RA—Crohn's disease	9.39e-06	9.67e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—JAK2—Crohn's disease	9.27e-06	9.54e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD4—Crohn's disease	9.26e-06	9.53e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IFNG—Crohn's disease	9.09e-06	9.36e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GPX4—Crohn's disease	9.04e-06	9.31e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TYK2—Crohn's disease	8.97e-06	9.23e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL2RA—Crohn's disease	8.91e-06	9.17e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—FADS1—Crohn's disease	8.81e-06	9.06e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD4—Crohn's disease	8.78e-06	9.04e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GCKR—Crohn's disease	8.73e-06	8.99e-05	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—IL6—Crohn's disease	8.6e-06	8.85e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	8.59e-06	8.84e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—JAK2—Crohn's disease	8.55e-06	8.8e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL1B—Crohn's disease	8.55e-06	8.8e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GPX4—Crohn's disease	8.25e-06	8.49e-05	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—IL6—Crohn's disease	8.16e-06	8.39e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL1B—Crohn's disease	8.11e-06	8.35e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CD4—Crohn's disease	8.11e-06	8.35e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PTGS2—Crohn's disease	8.05e-06	8.29e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GCKR—Crohn's disease	7.96e-06	8.2e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	7.63e-06	7.85e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—FADS1—Crohn's disease	7.52e-06	7.74e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—IL6—Crohn's disease	7.42e-06	7.63e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—STAT3—Crohn's disease	7.17e-06	7.38e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GPX4—Crohn's disease	7.05e-06	7.25e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SMAD3—Crohn's disease	6.83e-06	7.03e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GCKR—Crohn's disease	6.8e-06	7e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—STAT3—Crohn's disease	6.8e-06	7e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	6.67e-06	6.87e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TYK2—Crohn's disease	6.62e-06	6.81e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—JAK2—Crohn's disease	6.31e-06	6.5e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TYK2—Crohn's disease	6.28e-06	6.46e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—STAT3—Crohn's disease	6.28e-06	6.46e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	6.24e-06	6.42e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—JAK2—Crohn's disease	5.99e-06	6.17e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CXCL8—Crohn's disease	5.76e-06	5.93e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	5.69e-06	5.86e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CXCL8—Crohn's disease	5.47e-06	5.63e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	5.46e-06	5.62e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL6—Crohn's disease	5.01e-06	5.15e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	4.98e-06	5.12e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	4.86e-06	5.01e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ALB—Crohn's disease	4.82e-06	4.96e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL6—Crohn's disease	4.75e-06	4.89e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—STAT3—Crohn's disease	4.63e-06	4.77e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TYK2—Crohn's disease	4.45e-06	4.58e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—STAT3—Crohn's disease	4.4e-06	4.53e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IL6—Crohn's disease	4.39e-06	4.51e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	4.25e-06	4.38e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—JAK2—Crohn's disease	4.25e-06	4.37e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTGS2—Crohn's disease	4.22e-06	4.34e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CD4—Crohn's disease	4.03e-06	4.15e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ALB—Crohn's disease	3.83e-06	3.94e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ALB—Crohn's disease	3.6e-06	3.71e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ALB—Crohn's disease	3.6e-06	3.7e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ALB—Crohn's disease	3.4e-06	3.5e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL6—Crohn's disease	3.24e-06	3.33e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS2—Crohn's disease	3.15e-06	3.24e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS2—Crohn's disease	3.15e-06	3.24e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—STAT3—Crohn's disease	3.12e-06	3.21e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL6—Crohn's disease	3.07e-06	3.16e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS2—Crohn's disease	2.97e-06	3.06e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ALB—Crohn's disease	2.78e-06	2.86e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ALB—Crohn's disease	2.53e-06	2.61e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS2—Crohn's disease	2.43e-06	2.5e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS2—Crohn's disease	2.22e-06	2.28e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6—Crohn's disease	2.18e-06	2.24e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALB—Crohn's disease	2.17e-06	2.23e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS2—Crohn's disease	1.89e-06	1.95e-05	CbGpPWpGaD
